WebPhase III trials comparing the two regimens demonstrated that both FOLFOX and FOLFIRI provided similar response rates of 54% to 56%, as well as similar PFS rates of 8 months … WebApr 23, 2014 · Fuchs CS, Marshall J, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008, 26: 689-690. 10.1200/JCO.2007.15.5390. Article PubMed Google Scholar
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI ...
WebBackground. Patients (pts) with mCRC have few treatment options and poor outcome, particularly those with KRAS mutation (mKRAS). After failure of 1L treatment, the ORR for FOLFIRI/bev is 5-13%, with PFS 4-6 mos, and OS 10-12 mos. Onvansertib (Onv), is a highly specific PLK1 inhibitor, currently being investigated in combination with … WebApr 22, 2009 · J Clin Oncol. 2007, 25: 4779-4786. 10.1200/JCO.2007.11.3357. Article CAS PubMed Google Scholar Folprecht G, Gruenberger T, Hartmann JT, Lordick F, Stoehlmacher J, Bechstein W, Ockert D, Hermann T, Liersch T, Koehne C: Randomized multicenter study of cetuximab plus FOLFOX of plus FOLFIRI in neoadjuvant treatment … santa cruz county child welfare services
Protocol of the QUATTRO-II study: a multicenter randomized …
WebMar 18, 2011 · Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779–4786. Article PubMed CAS Google Scholar WebOct 31, 2013 · J Clin Oncol. 2007;25:4779–86. Article CAS PubMed Google Scholar Pectasides D, Papaxoinis G, Kalogeras KT, et al. XELIRI-bevacizumab versus FOLFIRI … WebFeb 7, 2011 · This is the first phase II study to evaluate the efficacy and tolerability of the first-line FOLFIRI, as well as the influence of uridine di ... Including the Analysis of UGT1A1*28/*6 Polymorphisms, Japanese Journal of Clinical Oncology, Volume 41, Issue 4, ... (irinotecan 180 mg/m 2), 85.9% reported by Tournigand et al. ... santa cruz county clerk appointment